Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
Gerald S. Falchook(The University of Texas MD Anderson Cancer Center), Leslie A. Fecher(University of Pennsylvania), Lori Roadcap(GlaxoSmithKline (United States)), Karl D. Lewis(University of Colorado Denver), Kevin B. Kim(The University of Texas MD Anderson Cancer Center), Keith T. Flaherty(Cancer Research Center), Johanna C. Bendell(Dana-Farber Cancer Institute), Peter J. O’Dwyer(University of Pennsylvania), Peng Sun(Philips (Finland)), Razelle Kurzrock(Medical College of Wisconsin), Nicholas J. Vogelzang(Comprehensive Cancer Centers of Nevada), Peter F. Lebowitz(GlaxoSmithKline (United States)), Michael S. Gordon(Pinnacle Oncology Hematology), Stephen A. Szabo(GlaxoSmithKline (United States)), Douglas J. DeMarini(GlaxoSmithKline (United States)), Howard A. Burris(Deaconess Hospital), Wells A. Messersmith(University of Colorado Cancer Center), Jeffrey R. Infante(Cancer Research Center), Ngocdiep T. Le(GlaxoSmithKline (United States)), René González(University of Miami), Vijay Peddareddigari(Autolus (United Kingdom)), Christopher Moy(GlaxoSmithKline (United States))
Cited by 541
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.3k
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k